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Abstract 
 
Background: Aspirin and other NSAIDs are widely used as analgesics and the 
former is a preventative agent for vascular events. It is unclear whether their long-
term use affects cancer risk. Data on the chemopreventative role of these drugs on 
the mortality in patients with upper aerodigestive tract cancer (UADT) are insufficient. 
The aim of this study was to investigate the effect of aspirin and other NSAIDs on 
survival in UADT cancer patients.  
 
Methods: An observational cohort study of patients with UADT cancer was 
undertaken using Primary Care Clinical Informatics Unit (PCCIU) database of 
electronic medical records in Scotland. Information was available on all prescriptions 
of aspirin and other NSAIDs before and after diagnosis. The main outcome measure 
was all-cause mortality. Cox regression was used for statistical data analysis. 
 
Results: There were 2,392 patients diagnosed with UADT cancer between 1996 and 
2010. Mean age of patients was 66 years (SD 12) and most were male (63%). Median 
survival in head and neck (HNC) patients was 94 months, while median survival in 
oesophageal cancer patients was 10 months. For HNC improved survival was 
observed with aspirin prescription (ever vs never Hazard Ratio (HR) 0.56 95% 
Confidence Interval (CI) 0.44, 0.71), there was no association with Cyclooxygenase 2 
Inhibitors (COX-2) prescriptions. Improved survival was observed with other NSAIDs 
prescription (ever vs never HR 0.74 95% CI 0.60, 0.90). For oesophageal cancer 
patients, improved survival was observed with aspirin prescriptions (ever vs never HR 
0.54 95% CI 0.45, 0.64), COX-2 prescriptions (HR 0.78 95% CI 0.62, 0.98) and other 
NSAIDs (HR 0.67 95% CI 0.56, 0.80). 
 
Conclusions: Aspirin and other NSAIDs prescriptions after diagnosis are associated 
with a reduced all-cause mortality in UADT cancer patients. 
 
Keywords: Aspirin; Non-steroidal anti-inflammatory agents; head and neck cancer; 
oesophageal cancer; survival; prognosis; Computerized Medical Records 
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1. Introduction 
Cancer of the upper aerodigestive tract (UADT) (oral cavity, pharynx, larynx and 
oesophagus combined) is, globally, the fourth most common cancer and cause of 
cancer mortality, with over million incident cases and over 700,000 deaths worldwide 
[1]. While a decrease in mortality was noted in the European Union (EU) overall 
between 1993 and 2004, a persistent rise was observed in central and eastern 
European countries [2]. European mean age-standardised 5-year relative survival was 
39.9% for Head and Neck Cancer (HNC) and 12.4% for cancer of the oesophagus [3]. 
 
Prophylactic aspirin has been considered to be beneficial in reducing the risks of heart 
disease and cancer. Previous research showed the decreased risk of cancer of the 
UADT associated with the use of non-COX-2 inhibitors, NSAIDs and long-term aspirin 
therapy [4,5]. Analysis of individual patient data from randomised clinical trials of daily 
aspirin [7] showed a significant reduction in death due to cancer, however there were 
no data reported in this study on HNC. Observational study by Rachidi et al [6] showed 
that post-diagnosis treatment of patients with head and neck squamous cell carcinoma 
with antiplatelet medications (including aspirin and other NSAIDs) was associated with 
better prognosis. 
 
The aim of this study was to investigate the effect of aspirin and other NSAIDs use on 
the risk of UADT cancers. Specific objectives were to investigate risk by cancer sub-
site, duration of use and type of NSAIDs. 
 
2. Material and Methods 
 
An observational cohort study of patients with UADT cancer was undertaken using 
Primary Care Clinical Informatics Unit (PCCIU) database of electronic medical records 
in Scotland (http://www.abdn.ac.uk/pcciu/). PCCIU Research database includes data 
from more than 200 participating medical practices and approximately one million 
patients. Data reflect the computerized clinical record, including appointments, repeat 
and acute prescribing, call/recall, and screening. Ethical permission was not required 
as the data were anonymised and individuals could not be identified. 
 
Patients with first time UADT cancer (oral cavity, oropharynx, hypopharynx, larynx and 
oesophagus) diagnosed in 1996 or later were identified using READ codes 
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(http://systems.hscic.gov.uk/data/uktc/readcodes) as described in Table 1. Carcinoma 
in situ and patients aged <18 years at diagnosis were excluded. We used all the 
available eligible patients in the PCCIU database. Participants with cancer diagnosis 
before diagnosis with UADT cancer were excluded (READ codes B0%, B1%, B2%, 
B3%, B4%, B5%, B6%, B9%, BA%, BB%, By%).  
 
Participants entered the study on the date of UADT cancer diagnosis and exited the 
study on the date of last appointment at their medical practice, date of deregistration 
with the practice or date of death. There was no information on cause of death. 
 
To measure exposure, we identified prescriptions of oral aspirin, Cyclooxygenase 2 
Inhibitors (COX-2) or other NSAIDs. Additional data in the database were available on 
patients’ age at diagnosis, gender, practice deprivation (Carstairs index) [8], self-
reported smoking status before diagnosis (never/ever) and most recent alcohol 
consumption (high consumption was defined as above the recommended limit of 2-3 
units a day for women and 3-4 units a day for men). Information was also obtained on 
history of coronary heart disease (CHD), atrial fibrillation (AF) and stroke.  
 
Analysis was conducted using IBM SPSS Statistics version 21 (IBM Corporation 
2012) and STATA 13 (StataCorp LP, College Station, TX, USA 2013). We used 
Kaplan-Meier analysis to illustrate survival graphically and Log Rank test (Mantel-
Cox) to test for equality of survival distributions for different levels of medication use. 
 
Hazard Ratios (HRs) with 95% confidence intervals (CIs) adjusted for the potential 
confounding factors (age, gender, deprivation, smoking and alcohol consumption) 
were estimated using Cox regression model. Proportional hazards assumption was 
tested using stphtest and stphplot procedures in STATA. Continuous variables were 
categorised using median or tertiles of the overall distribution as appropriate. Age 
was a priori categorised as following: 18-55, 56-65, 66-75 and 76-99 years. Multiple 
imputation with ten imputed datasets was performed using mi procedure in STATA 
for smoking and alcohol consumption with all variables used in the analysis included 
in the imputation [9].  
 
Additional analysis was conducted using nested case-control design. Those who had 
died were considered cases. These were matched on gender, age (within 5-years) 
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and year of cancer diagnosis (within 2-years) separately for each site to one control 
who lived at least as long after diagnosis as the matched case. Conditional logistic 
regression was used to estimate Odds Ratios (ORs) with 95% CI adjusted for the 
potential confounding factors. 
 
3. Results 
 
We identified 2,392 patients with UADT cancer (1,195 of HNC and 1,197 oesophageal 
cancer) from 131 general medical practices (Table 1) between 1996 and 2010. Mean 
age of patients at diagnosis was 62 (SD 12) and 69 (SD 11) for HNC and oesophageal 
cancer respectively. The majority were males (70.2% among HNC patients and 64.4% 
among oesophageal cancer patients). There were 509 (42.6%) and 965 (80.6) deaths 
among HNC and oesophageal cancer patients, respectively. Median survival in HNC 
patients was 94 months (95% Confidence Interval (CI) 78, 120), while median survival 
in oesophageal cancer patients was 10 months (95% CI 9, 11). 
 
Older age, male gender, deprivation, smoking, high (above the recommended limit) 
alcohol consumption, AF and stroke associated with poor survival in HNC patients. 
Among patients with oesophageal cancer, poor survival was associated with older 
age, male gender, smoking, CHD, AF, stroke and aspirin prescription before diagnosis 
(Table 2). For both cancer sites, 'later entry to the cohort was associated with shorter 
survival: HR 2.01 (95% CI 1.56, 2.60) in HNC patients and HR 1.64 (95% CI 1.36, 
1.98) in oesophageal cancer patients diagnosed in 2006-2010 compared with 1996-
2000. 
 
Figure 1 shows survival by cancer site and medication. Results of the Log Rank test 
for HNC for aspirin, Cox-2 and other NSAIDs were 6.75 (P=0.009), 2.34 (P=0.126) 
and 27.43 (P>0.001) respectively. Results of the Log Rank test for oesophageal 
cancer were 10.31 (P=0.001) for aspirin, 6.69 (P=0.01) for Cox-2 and 31.34 (P<0.001) 
for other NSAIDs. 
 
For HNC, improved survival was observed with aspirin prescription (ever vs never HR 
0.56 95% CI 0.44, 0.71), higher prescription density (defined as number of prescription 
divided by total follow up time) (HR 0.55, 95% CI 0.36, 0.84 for more than 6 
prescriptions per year). There was no difference in prescription timing of aspirin: both 
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first aspirin prescription within the first month (HR 0.48 95% CI 0.29, 0.81) and first 
prescription later (HR 0.70 95% CI 0.54, 0.91) associated with a reduced mortality 
(Table 3). There was no association with ever COX-2 prescriptions but increased risk 
with increased prescription density (HR 3.58 95% CI 1.81, 7.10 for 3 or more 
prescriptions per year) and for first prescription within a month since diagnosis (HR 
4.95 95% CI 3.03, 8.09). However, these results are based on a limited number of 
patients and deaths. Improved survival was observed with other NSAIDs prescription 
(ever vs never HR 0.74 95% CI 0.60, 0.90). Low prescription density of other NSAIDs 
(<3 per year) showed a reduction in HR (0.77 95% CI 0.60, 1.00) however higher 
prescription density (≥3 prescriptions per year) was associated with increased risk of 
death (HR 1.65 95% CI 1.04, 2.63). 
 
For oesophageal cancer patients, improved survival was observed with medicines of 
interest: aspirin prescriptions (ever vs never HR 0.54 95% CI 0.45, 0.64), COX-2 
prescriptions (HR 0.78 95% CI 0.62, 0.98) and other NSAIDs (HR 0.67 95% CI 0.56, 
0.80) (Table 3). 
 
Using nested case-control design, there were 509 cases of deaths among HNC 
patients and 232 cases of deaths among oesophageal cancer patients with 1-to-1 
matched controls. For aspirin, COX-2 and other NSAIDs prescriptions (ever vs never) 
ORs were as following: 0.85 (95% CI 0.62, 1.17), 1.32 (95% CI 0.69, 2.50) and 0.82 
(95% CI 0.62, 1.08) for HNC and 0.75 (95% CI 0.43, 1.31), 0.70 (95% CI 0.15, 3.20) 
and 1.05 (95% CI 0.60, 1.84) for oesophageal cancer.  
 
4. Discussion 
 
This first large Scotland-based general practice-derived study of survival showed a 
decrease in risk of UADT cancer with aspirin prescriptions irrespective of timing after 
diagnosis or volume.  
 
Other studies of cancer patients showed improved survival among those taking 
aspirin. In meta-analysis of eight trials (25 570 patients, 674 cancer deaths), allocation 
to aspirin reduced death due to cancer (pooled Odds Ratio (OR) 0.79, 95% CI 0.68-
0.92) [7]. In further analysis of individual patient data from seven randomised trials of 
daily aspirin versus no aspirin, there were no data reported specifically on head and 
neck cancer, but there was a non-significant decrease in risk of death due to 
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oesophageal cancer (HR 0.78 95% CI 0.27, 2.23 for 0-5 years of follow up and HR 
0.43 95% CI 0.11, 1.72 for 5 years follow up or longer) [7]. 
 
Study of aspirin use and survival after diagnosis of breast cancer showed a reduction 
in both all-cause (HR 0.53, 95% CI 0.45, 0.63) and breast-cancer specific mortality 
(HR 0.42, 95% CI 0.31, 0.55) [10]. In a prospective, observational study of aspirin 
and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an 
adjuvant chemotherapy trial, aspirin use and COX-2 inhibitors use were associated 
with improved overall survival (HR 0.63, 95% CI 0.35 to 1.12) and 0.50 (95% CI 0.23 
to 1.07), respectively [11]. Study of treatment with antiplatelet medications (including 
aspirin and other NSAIDs) after diagnosis with head and neck squamous cell 
carcinoma was associated with longer overall survival [HR 0.76, 95% CI 0.58-0.99] 
[6]. 
 
The chemopreventive effect of aspirin and other NSAIDs has been partially attributed 
to their inhibition of the cyclo-oxygenase (COX) enzymes and reduced production of 
prostaglandins and other inflammatory mediators [7]. Platelets play a multifaceted 
and important role in cancer biology [12] and therefore development of platelet 
inhibitors that influence malignancy progression and study of currently available 
antiplatelet drugs represents a promising area of targeted cancer therapy [12 , 6].  
IEW ARTICLE 
The strength of this study is that as results are likely to be representative of the general 
population because the majority of the UK population is registered with a general 
medical practice.  
 
However the study has several methodological deficiencies. The study had a limited 
sample size particularly for investigation of prescription density and prescription 
timing. No information was available regarding the histological sub-type, cancer 
stage or treatment. We could only investigate all-cause mortality as there was no 
information on cause of death. Study by Ning et al [13] reported that while cancer is 
the major cause of death among cancer patients, approximately half of participants 
died from other diseases and complications, such as cardiovascular and respiratory 
diseases. The authors concluded that clinicians and cancer survivors should pay 
attention to the prevention and treatment of other diseases and complications.  
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For both cancer sites, 'later entry to the cohort was associated with shorter survival. 
These results may reflect differences in diagnostic tools, changes in clinical guidelines 
over time or some other residual confounding. 
 
NSAID exposure was measured in terms of prescriptions issued and we did not have 
reliable information on dose or indication for use of aspirin or other NSAIDs. However 
Rothwell et al [7] reported that benefit of taking aspirin on cancer death was unrelated 
to aspirin dose (75 mg upwards). While low dose aspirin is mostly prescribed for 
prevention of cardiovascular events, other NSAIDs may be prescribed for cancer pain 
[14,15]. The issue of a prescription does not mean that the medicine was actually 
used. A questionnaire-based study conducted in UK general medical practices which 
compared prescribed NSAIDs and described by patients reported mean (SD) 
compliance (percentage of intended dose taken) of 0.73 (0.55) for Ibuprofen, 0.76 
(0.56) for diclofenac and 0.76 (0.55) for naproxen [19].  
 
No data were available regarding the use of over-the-counter medications which 
contain aspirin and NSAIDs, and this will have under-estimated exposure to these 
medicines. COX-2 inhibitors can only be obtained by prescription in the UK. However 
the reported prevalence of aspirin prescription is comparable with prevalence of self-
reported aspirin use in other studies conducted in the UK [5] (22% in patients with 
UADT cancer and 26% in healthy participants). Immeasurable time bias [16] could 
also have affected the results as the included patients might have been hospitalised 
and received drugs without there being a record in the general medical practice. 
However there was no data on hospitalisations available in the database.   
 
Using 'ever' vs. 'never' categories for drug exposure also introduces immortal time 
bias [17] because it assumes that all participants had exposure to a drug from the 
start of follow-up. In observational studies some patients may not have survived to 
the day of their first prescription during follow-up, and may therefore have been 
classified as 'never users'. This could result in over-estimation of hazard ratios for 
'ever' exposure to a drug. However unlike some treatments that may not be 
immediately available such as operations, aspirin (and some other NSAIDs) are 
easily available. In addition, we had prescription information both before and after 
diagnosis. In case of aspirin, the majority of patients (55% with HNC and 77% with 
oesophageal cancer) who were prescribed aspirin after diagnosis also had 
9 
 
prescriptions before diagnosis. They were more likely to be continuous users and 
therefore exposed at baseline. To investigate this bias further, sensitivity analysis 
was conducted using nested case-control design to test the validity of the results 
[18]. This analysis showed moderate non-significant reduction in risk of death 
associated with aspirin prescription for both HNC and oesophageal cancer. To 
reduce immortal time bias, future larger studies should investigate the use Cox 
models with time-dependent exposures. Such models will need to assess the length 
of prescriptions and to clarify the longest acceptable gap between prescriptions that 
constitute 'continuous use'. Such a model would also facilitate the addressing of 
issues such as increased risks of bleeding (aspirin and NSAID users) and increased 
risks of cardiovascular events, a common cause of death (NSAID and COX2 users). 
 
Hernández-Díaz and García Rodríguez [20] in the study of NSAIDs and risk of lung 
cancer performed a sensitivity analysis to quantify the impact of misclassification due 
to unrecorded over-the-counter use or to non-compliance. They concluded that the 
protective effect could not be explained by the unrecorded use. Yood et al [21] 
concluded from their sensitivity analysis that prescription data can give valid estimates 
of association even though some of the drugs are available over-the-counter.  
 
We defined ever users as those with at least one prescription. Another study of 
prescriptions [22] similarly defined users as those with at least one prescription, 
while Friis et al [23] defined users as those with two or more prescriptions. Studies 
which collected information using questionnaires defined users as those who ever 
taken aspirin before the onset of illness [24] or as regular users (use at least once a 
week for a year) [5].  
 
While we adjusted for potential confounders such as deprivation, smoking and 
alcohol consumption, the quality of some of this information was poor. For example, 
there was a large amount of missing data for smoking (24%) and alcohol 
consumption (35%). We also used multiple imputation to replace the missing values 
for confounding factors. 
 
In addition, we did not have information on other factors such history of HPV 
infection. It was shown that tumour HPV status is a strong and independent 
prognostic factor for survival among patients with oropharyngeal cancer [25]. 
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There are risks associated with long term use of aspirin. A systematic review of 
observation studies of NSAIDs use showed an increased pooled Relative Risk of 3.8 
(95% CI 3.6, 4.1) of upper gastrointestinal tract bleeding and perforation [26]. 
However Rothwell et al [27] in the study of individual patient data from 51 
randomised trials of short-term effects of daily aspirin on cancer incidence, mortality, 
and non-vascular death showed that the reduced risk of major vascular events was 
initially offset by an increased risk of major bleeding, but effects on both outcomes 
diminished with increasing follow-up, leaving only the reduced risk of cancer from 3 
years onwards. Case-fatality from major extracranial bleeds was also lower on 
aspirin than on control (Odds Ratio (OR) 0·32, 95% CI 0·12, 0·83). 
 
Population-based cross-sectional European Eye Study of participants 65 years of 
age and older, showed that frequent aspirin use was associated with early and late 
aging macula disorder (AMD), and the ORs rose with increasing frequency of 
consumption. For daily aspirin users, the ORs, showed an increase with increasing 
severity of AMD grades: grade 1, 1.26 (95% CI 1.08, 1.46); grade 2, 1.42 (95% CI 
1.18, 1.70), and wet late AMD, 2.22 (95% CI, 1.61, 3.05) [28]. 
Analysis of benefits and harms of prophylactic use of aspirin in the general 
population [29] suggested that in order to improve the benefit-harm ratio, future 
studies could identify individuals at high-risk of bleeding and either reduce their risk 
or not offer them prophylactic aspirin. Contraindications include peptic ulcer, recent 
bleeding episodes or bleeding tendencies. Other risk factors for bleeding in aspirin or 
NSAID users are increasing age, male sex, diabetes, hypertension, being overweight 
or obese, smoking, alcohol consumption and H. pylori infection [30]. 
 
Conclusion 
Aspirin and other NSAIDs prescriptions after diagnosis are associated with a 
reduced all-cause mortality in UADT cancer patients.These results should be 
replicated in other prescriptions databases using statistical models with time-
dependent exposures and different study designs. Further research is also needed 
to determine the optimum dose and duration of use, and to identify individuals at 
increased risk of bleeding before starting aspirin prophylaxis. 
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Table 1.  Description of patients with UADT cancer included in the study 
 
Characteristics 
 
Head and neck  
 
Oesophagus 
 
Malignant neoplasm N (%) N (%) 
READ 
code 
Site 1195 (100) 1197 (100) 
 
B0... 
B01% 
B03% 
B04% 
B05% 
B06% 
B08% 
B0z% 
 
B21% 
B901% 
 
B906% 
 
B10% 
B100. 
B101 
B102 
B104 
B105 
B107 
B10y 
B10z 
lip, oral cavity and pharynx 
tongue 
gum 
floor of mouth 
other & unspecified parts of mouth 
oropharynx 
hypopharynx 
other and ill-defined sites within the lip, oral 
cavity and pharynx 
larynx 
neoplasm of uncertain behaviour of lip, oral 
cavity and pharynx 
neoplasm of uncertain behaviour of larynx 
 
oesophagus 
cervical oesophagus 
thoracic oesophagus 
abdominal oesophagus 
middle third of oesophagus 
lower third of oesophagus 
other specified part of oesophagus 
oesophagus not otherwise specified 
100 (4.2) 
143 (6.0) 
4 (.2) 
51 (2.1) 
87 (3.6) 
123 (5.1) 
47 (2.0) 
161 (6.7) 
 
423 (17.7) 
 
40 (1.7) 
16 (.7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
387 (16.2) 
3 (.1) 
2 (.1) 
12 (.5) 
1 (.04) 
29 (1.2) 
1 (.04) 
762 (31.9) 
Age at diagnosis (years) 
Mean (SD) 
Min, Max 
 
62.3 (11.9) 
20, 95 
 
69.3 (11.4) 
25, 99 
Gender 
M 
F 
 
839 (70.2) 
356 (29.8) 
 
771 (64.4) 
426 (35.6) 
Duration of follow up (months) 
Median (IQR) 
Min, Max 
 
34.9 (64.1) 
1, 181 
 
9.0 (15.9) 
1, 181 
Follow up data for at least 12 months 
N (%) 
 
919 (76.9) 
 
470 (32.3) 
Mortality 
N (%)  
 
509 (42.6) 
 
965 (80.6) 
Survival (months)  
Median (95% CI) 
 
94 (78, 120) 
 
10 (9, 11) 
 
IQR – interquartile range 
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Table 2. Factors associated with all-cause mortality in UADT cancer patients 
 
Characteristic 
 
HNC cancer 
(n=1,195) 
Oesophageal cancer 
(n=1,197) 
N N (%) died Hazard ratio 
(95% CI) # 
N N (%) died Hazard ratio 
(95% CI) # 
Age at diagnosis 
18-55 
56-65 
66-75 
76-99 
 
321 
391 
333 
150 
 
92 (28.7) 
161 (41.2) 
162 (48.65) 
94 (62.67) 
 
1.00 
1.56 (1.21, 2.02) 
2.10 (1.63, 2.72) 
4.05 (3.02, 5.43) 
 
144 
277 
375 
401 
 
106 (73.6) 
210 (75.8) 
299 (79.7) 
350 (87.3) 
 
1.00 
1.24 (0.98, 1.56) 
1.38 (1.10, 1.72) 
1.93 (1.54, 2.41) 
Gender 
M 
F 
 
839 
356 
 
374 (44.6) 
135 (37.9) 
 
1.00 
0.75 (0.62, 0.92) 
 
771 
427 
 
627 (81.3) 
338 (79.3) 
 
1.00 
0.86 (0.75, 0.98) 
Carstairs 
Deprivation  
1 (most affluent) 
2 
3 
4 
5 
6 
7 (most deprived) 
 
 
55 
85 
154 
406 
186 
135 
174 
 
 
17 (30.9) 
26 (30.6) 
61 (39.6) 
172 (42.4) 
80 (43.0) 
69 (51.1) 
84 (48.3) 
 
 
1.00 
1.36 (0.74, 2.50) 
1.16 (0.68, 2.00) 
1.68 (1.02, 2.77) 
1.54 (0.91, 2.62) 
2.10 (1.24, 3.58) 
2.14 (1.27, 3.60) 
 
 
39 
114 
250 
379 
194 
124 
97 
 
 
33 (84.6) 
89 (78.1) 
203 (81.2) 
301 (79.4) 
156 (80.4) 
100 (80.7) 
83 (85.6) 
 
 
1.00 
1.04 (0.69, 1.55) 
0.96 (0.66, 1.38) 
0.99 (0.69, 1.41) 
1.05 (0.72, 1.54) 
0.93 (0.63, 1.38) 
1.22 (0.81, 1.83) 
Year of diagnosis 
1996-2000 
2001-2005 
2006-2010 
 
303 
420 
472 
 
145 (47.9) 
204 (48.6) 
160 (33.9) 
 
1.00 
1.48 (1.18, 1.87) 
2.01 (1.56, 2.60) 
 
219 
487 
491 
 
184 (84.0) 
417 (85.6) 
364 (74.1) 
 
1.00 
1.48 (1.24, 1.77) 
1.64 (1.36, 1.98) 
Smoking  
Never  
Ever 
Missing 
 
141 
752 
302 
 
34 (24.1) 
337 (44.8) 
371 (41.6) 
 
1.00 
2.33 (1.62, 3.35) 
 
312 
618 
267 
 
246 (78.9) 
498 (80.6) 
 
1.00 
1.21 (1.04, 1.42) 
Alcohol 
consumption 
No / Low 
High ## 
Missing 
 
 
630 
135 
430 
 
 
253 (40.2) 
63 (46.7) 
 
 
1.00 
1.52 (1.14, 2.06) 
 
 
728 
64 
405 
 
 
586 (80.5) 
50 (78.1) 
 
 
 
1.00 
1.20 (0.89, 1.62) 
CHD  
No 
Yes 
 
1005 
190 
 
415 (41.3) 
94 (49.5) 
 
1.00 
0.95 (0.75, 1.20) 
 
970 
227 
 
769 (79.3) 
196 (86.3) 
 
1.00 
1.23 (1.04, 1.44) 
AF  
No 
Yes 
 
1153 
42 
 
482 (41.8) 
27 (64.3) 
 
1.00 
1.67 (1.12, 2.49) 
 
1127 
70 
 
900 (79.9) 
65 (92.9) 
 
1.00 
1.32 (1.02, 1.70) 
Stroke  
No 
Yes 
 
1132 
63 
 
477 (42.1) 
32 (50.8) 
 
1.00 
1.50 (1.04, 2.15) 
 
1143 
54 
 
922 (80.7) 
43 (79.6) 
 
1.00 
1.39 (1.02, 1.89) 
Aspirin 
prescription 
before diagnosis 
No 
Yes 
 
 
 
886 
309 
 
 
 
366 (41.3) 
143 (46.3) 
 
 
 
1.00 
1.11 (0.90, 1.36) 
 
 
 
810 
387 
 
 
 
629 (77.7) 
336 (86.8) 
 
 
 
1.00 
1.38 (1.20, 1.59) 
COX-2 
prescription 
before diagnosis 
No 
Yes 
 
 
 
1145 
50 
 
 
 
488 (42.6) 
21 (42.0) 
 
 
 
1.00 
0.99 (0.64, 1.54) 
 
 
 
1128 
69 
 
 
 
916 (81.2) 
49 (71.0) 
 
 
 
1.00 
0.94 (0.71, 1.26) 
Other NSAID 
before diagnosis 
No 
Yes 
 
 
763 
432 
 
 
349 (45.7) 
160 (37.0) 
 
 
1.00 
0.94 (0.78, 1.14) 
 
 
759 
438 
 
 
618 (81.4) 
347 (79.2) 
 
 
1.00 
1.11 (0.97, 1.26) 
 
# From Cox regression adjusted for age, gender and deprivation      
## High consumption is defined as above the recommended limit 
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Table 3. Aspirin, COX-2 and Other NSAIDs prescriptions after diagnosis of 
UADT cancer and all-cause mortality 
 
 Head and Neck cancer 
(n=1,195) 
Oesophageal cancer 
(n=1,197) 
Prescription 
 
N  
 
N (%) 
died 
Hazard ratio 
(HR) ## 
N N (%) 
died 
Hazard ratio 
(HR) ## 
Aspirin  
Any after diagnosis 
Never 
Ever 
 
Prescription density# 
Never 
<3 per year 
3-6 per year 
>6 per year 
 
First prescription 
timing after diagnosis# 
No 
Within the 1st month 
Later 
 
 
779 
416 
 
 
566 
156 
101 
96 
 
 
 
566 
220 
133 
 
 
331 (42.5) 
178 (42.8) 
 
 
195 (34.5) 
65 (41.7) 
32 (31.7) 
40 (41.7) 
 
 
 
195 (34.5) 
33 (37.1) 
104 (39.4) 
 
 
1.00 
0.56 (0.44, 0.71) 
 
 
1.00 
0.81 (0.60, 1.09) 
0.48 (0.33, 0.71) 
0.55 (0.36, 0.84) 
 
 
 
1.00  
0.48 (0.29, 0.81) 
0.70 (0.54, 0.91) 
 
 
935 
262 
 
 
346 
53 
38 
33 
 
 
 
346 
45 
79 
 
 
756 (80.9) 
209 (79.8) 
 
 
232 (67.1) 
34 (64.2) 
24 (63.2) 
26 (78.8) 
 
 
 
232 (67.1) 
35 (77.8) 
49 (62.0) 
 
 
1.00 
0.54 (0.45, 0.64) 
 
 
1.00 
0.67 (0.45, 0.99) 
0.65 (0.43, 0.99) 
0.82 (0.53, 1.29) 
 
 
 
1.00  
0.81 (0.49, 1.34) 
0.66 (0.48, 0.90) 
COX-2  
Any after diagnosis 
Never 
Ever 
 
Prescription density# 
Never 
<3 per year 
3+ per year 
 
First prescription 
timing after diagnosis# 
No 
Within the 1st month 
Later 
 
 
1142 
53 
 
 
868 
46 
5 
 
 
 
868 
4 
47 
 
 
484 (42.4) 
25 (47.2) 
 
 
309 (35.6) 
20 (43.5) 
3 (60.0) 
 
 
 
309 (35.6) 
4 (100.0) 
19 (40.4) 
 
 
1.00 
0.81 (0.53, 1.24) 
 
 
1.00 
0.85 (0.50, 1.43) 
3.58 (1.81, 7.10) 
 
 
 
1.00  
4.95 (3.03, 8.09) 
0.80 (0.49, 1.33) 
 
 
1168 
29 
 
 
450 
17 
3 
 
 
 
450 
- 
20 
 
 
941 (80.6) 
24 (82.8) 
 
 
300 (66.7) 
13 (76.5) 
3 (100) 
 
 
 
300 (66.7) 
- 
16 (80.0) 
 
 
1.00 
0.78 (0.62, 0.98) 
 
 
1.00 
1.14 (0.79, 1.85) 
1.08 (0.39, 2.97) 
 
 
 
1.00  
- 
1.18 (0.76, 1.84) 
Other NSAID  
Any after diagnosis 
Never 
Ever 
 
Prescription density# 
Never 
<3 per year 
3+ per year 
 
First prescription 
timing after diagnosis# 
Never 
Within the 1st month 
Prescription after 1st 
month of follow up 
 
 
773 
422 
 
 
541 
315 
63 
 
 
 
541 
53 
325 
 
 
347 (44.9) 
162 (38.4) 
 
 
198 (36.6) 
102 (32.4) 
32 (50.8) 
 
 
 
198 (36.6) 
19 (35.9) 
115 (35.4) 
 
 
1.00 
0.74 (0.60, 0.90) 
 
 
1.00 
0.77 (0.60, 1.00) 
1.65 (1.04, 2.63) 
 
 
 
1.00  
1.04 (0.64, 1.70) 
0.86 (0.66, 1.11) 
 
 
1032 
165 
 
 
366 
93 
11 
 
 
 
366 
9 
95 
 
 
840 (81.4) 
125 (75.8) 
 
 
250 (68.3) 
58 (62.4) 
8 (72.7) 
 
 
 
250 (68.3) 
4 (44.4) 
62 (65.3) 
 
 
1.00 
0.67 (0.56, 0.80) 
 
 
1.00 
0.78 (0.59, 1.04) 
1.28 (0.56, 2.92) 
 
 
 
1.00  
0.59 (0.26, 1.34) 
0.84 (0.64, 1.11) 
 
# Among those surviving for more than 12 months 
 
## Adjusted for age, gender, deprivation, year of diagnosis, smoking (ever), alcohol consumption 
(high), CHD, AF, Stroke, Aspirin ((before and after diagnosis ), COX-2 (before and after diagnosis), 
other NSAID (before and after diagnosis) and taking into account clustering within medical practices 
 
Prescription density was calculated as Number of prescriptions divided by follow up time   
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Figure 1. Prescriptions after diagnosis and survival 
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